Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer

Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease

(2017) Manish A. Shah et al.   Journal of the National Comprehensive Cancer Network

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

(2014) Akiko Kawano Nagatsuma et al.   Gastric Cancer

Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients

(2014) Long Liu et al.   TUMOR BIOLOGY

IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation

(2013) E Smith et al.   BRITISH JOURNAL OF CANCER

Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma

(2012) Wei An et al.   ANNALS OF SURGICAL ONCOLOGY

IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors

(2012) V. Evdokimova et al.   Science Signaling

The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis

(2011) Rania B. Georges et al.   CANCER BIOLOGY & THERAPY

IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma

(2011) Yoshito Tomimaru et al.   INTERNATIONAL JOURNAL OF CANCER

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Trend in gastric cancer: 35 years of surgical experience in Japan

(2011) Keishi Yamashita   WORLD JOURNAL OF GASTROENTEROLOGY

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Gastric Cancer—An Enigmatic and Heterogeneous Disease

(2010) Manish A. Shah   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

(2008) J. Matsubara et al.   CLINICAL CANCER RESEARCH

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY